JP2015504057A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504057A5
JP2015504057A5 JP2014550478A JP2014550478A JP2015504057A5 JP 2015504057 A5 JP2015504057 A5 JP 2015504057A5 JP 2014550478 A JP2014550478 A JP 2014550478A JP 2014550478 A JP2014550478 A JP 2014550478A JP 2015504057 A5 JP2015504057 A5 JP 2015504057A5
Authority
JP
Japan
Prior art keywords
chromen
pyrazin
pyridin
methylimidazo
dimethylimidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014550478A
Other languages
English (en)
Japanese (ja)
Other versions
JP6193881B2 (ja
JP2015504057A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/071899 external-priority patent/WO2013101974A1/en
Publication of JP2015504057A publication Critical patent/JP2015504057A/ja
Publication of JP2015504057A5 publication Critical patent/JP2015504057A5/ja
Application granted granted Critical
Publication of JP6193881B2 publication Critical patent/JP6193881B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014550478A 2011-12-30 2012-12-28 脊髄性筋萎縮症を治療するための化合物 Active JP6193881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161582064P 2011-12-30 2011-12-30
US61/582,064 2011-12-30
PCT/US2012/071899 WO2013101974A1 (en) 2011-12-30 2012-12-28 Compounds for treating spinal muscular atrophy

Publications (3)

Publication Number Publication Date
JP2015504057A JP2015504057A (ja) 2015-02-05
JP2015504057A5 true JP2015504057A5 (enExample) 2016-02-12
JP6193881B2 JP6193881B2 (ja) 2017-09-06

Family

ID=48698624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014550478A Active JP6193881B2 (ja) 2011-12-30 2012-12-28 脊髄性筋萎縮症を治療するための化合物

Country Status (10)

Country Link
US (2) USRE47689E1 (enExample)
EP (1) EP2797592B1 (enExample)
JP (1) JP6193881B2 (enExample)
KR (1) KR102057351B1 (enExample)
CN (1) CN104244944B (enExample)
BR (1) BR112014016287B1 (enExample)
CA (1) CA2861609C (enExample)
EA (1) EA029984B1 (enExample)
MX (1) MX352861B (enExample)
WO (1) WO2013101974A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014018027B1 (pt) 2012-01-26 2020-10-27 Ptc Therapeutics, Inc composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn
EP2812004B1 (en) 2012-02-10 2018-06-27 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
BR112014021531B1 (pt) 2012-03-01 2022-10-04 Ptc Therapeutics, Inc. Composto, composição farmacêutica e usos dos mesmos
CN104470909B (zh) 2012-03-23 2018-04-24 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
EA201500699A1 (ru) * 2012-12-24 2015-12-30 Рамот Эт Тель-Авив Юниверсити Лтд. Агенты для лечения генетических заболеваний, возникающих в результате нонсенс-мутаций, и способы идентификации этих агентов
CN103360269B (zh) * 2013-07-16 2015-07-08 临海市联盛化学有限公司 一种3-氯-2-氨基苯酚的制备方法
MX372669B (es) 2013-08-19 2020-04-23 Hoffmann La Roche Un compuesto que modifica el empalme del gen de foxm1 para usarse en la profilaxis o tratamiento de cáncer.
WO2015095449A1 (en) * 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
BR112016023811B8 (pt) 2014-04-22 2023-01-10 Piqur Therapeutics Ag Método para fabricação para derivados de triazina, pirimidina e piridina, seus intermediários e seus métodos de fabricação
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
HRP20230637T1 (hr) 2014-05-15 2023-09-29 F. Hoffmann - La Roche Ag Postupak za proizvodnju spojeva korisnih za liječenje spinalne mišićne atrofije
CA2952895C (en) * 2014-06-25 2023-09-26 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
KR102162062B1 (ko) 2015-11-12 2020-10-07 에프. 호프만-라 로슈 아게 척수성 근위축증의 치료용 조성물
CN108137601A (zh) * 2015-11-12 2018-06-08 豪夫迈·罗氏有限公司 用于治疗肌萎缩性侧索硬化症的化合物
US20200262800A1 (en) * 2015-11-16 2020-08-20 Ptc Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
CN108697709A (zh) 2015-12-10 2018-10-23 Ptc医疗公司 用于治疗亨廷顿病的方法
JP6872550B2 (ja) 2015-12-10 2021-05-19 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 架橋されたピペリジン誘導体
EP3419981A4 (en) * 2016-02-23 2019-09-18 Indiana University Research & Technology Corporation COMBINATION THERAPIES FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
CN108779115B (zh) 2016-10-14 2021-02-26 江苏恒瑞医药股份有限公司 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
AU2017363369A1 (en) 2016-11-28 2019-05-30 Ptc Therapeutics, Inc Methods for modulating RNA splicing
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
US11608501B2 (en) 2017-06-14 2023-03-21 Ptc Therapeutics, Inc. Methods for modifying RNA splicing
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
MX2020002711A (es) 2017-09-22 2020-07-20 Hoffmann La Roche Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EP3816160A4 (en) 2018-06-27 2022-03-16 Reborna Biosciences, Inc. PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY
US20220071953A1 (en) * 2019-01-08 2022-03-10 Texas Tech University System Small Molecule Analogs Of The Protein E4ORF1 In The Treatment And Prevention Of Metabolic Disorders
CN114007613A (zh) 2019-02-05 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
JP7603595B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
IL279674B2 (en) 2019-03-01 2025-04-01 Illumina Cambridge Ltd Amine-modified exocyclic coumarins and their use as fluorescent tags
CN109943092A (zh) * 2019-04-09 2019-06-28 浙江工业大学 具有高荧光量子产率的咪唑类香豆素类染料及其合成方法
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
PL4031547T3 (pl) 2019-09-18 2024-10-07 Takeda Pharmaceutical Company Limited Inhibitory kalikreiny osoczowej i ich zastosowania
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
CN110862395B (zh) * 2019-11-13 2020-09-29 株洲千金药业股份有限公司 一种制备他达拉非重要杂质的原料化合物的制备方法
CN114315807B (zh) * 2022-01-05 2023-09-15 江南大学 一种吡啶鎓盐光引发剂及其制备方法和应用
AU2024286618A1 (en) * 2023-06-09 2025-10-30 F. Hoffmann-La Roche Ag Inducible gene expression system
US12180195B1 (en) 2023-11-01 2024-12-31 King Faisal University 6-(6-bromo-2-oxo-2H-chromen-3-yl)-4-(2,4-dichlorophenyl)-2-alkoxynicotinonitrile as an antimicrobial compound
WO2025111409A1 (en) * 2023-11-21 2025-05-30 Biogen Ma Inc. Heterocyclic compounds of formula (i) for use in the treatment of spinal muscular atrophy via modulation of smn2 splicing

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1020636B (de) 1954-11-12 1957-12-12 Geigy Ag J R Verfahren zur Herstellung von 3-Phenyl-7-acylamino-cumarinen
CH419146A (de) * 1961-04-27 1966-08-31 Geigy Ag J R Verfahren zur Herstellung von 3-Phenyl-7-pyrazolyl-cumarinen
US3311636A (en) * 1963-03-14 1967-03-28 Upjohn Co Organic chemical compounds and process
DE1245306B (de) * 1963-05-11 1967-07-27 Bayer Ag Aufhellungsmittel
DE1594845C3 (de) 1966-03-19 1982-05-19 Bayer Ag, 5090 Leverkusen Substituierte v-Triazol-(2)-yl-cumarinverbindungen und deren Verwendung als Aufhellungsmittel
CH505089A (de) * 1968-08-23 1971-03-31 Bayer Ag Verfahren zur Herstellung von 3-substituierten-7-Aminocumarinen
JPS5023687B2 (enExample) 1972-03-07 1975-08-09
CH620322B (de) 1976-03-26 Ciba Geigy Ag Verwendung von 3-phenyl-7-(v-triazol-2-yl)-cumarinen zum optischen aufhellen von organischen materialien.
FR2361680A1 (fr) 1976-08-11 1978-03-10 Du Pont Plaques d'impression planographiques et leur preparation
DE2807761A1 (de) 1978-02-23 1979-08-30 Basf Ag Cumarinderivate
DE2815956A1 (de) * 1978-04-13 1979-10-18 Bayer Ag Verfahren zur herstellung von in 2-stellung substituierten triazolen-1,2,3
DE2950291A1 (de) * 1979-12-14 1981-06-19 Basf Ag, 6700 Ludwigshafen Neue cumarinverbindungen und verfahren zur herstellung von cumarinverbindungen
JPS56140990A (en) 1980-04-07 1981-11-04 Showa Kagaku Kogyo Kk 3-phenylcoumarin derivative bearing dicarbonylimide group
DE3101141A1 (de) 1981-01-16 1982-09-02 Bayer Ag, 5090 Leverkusen Triazolylcumarinverbindungen, sowie deren herstellung und verwendung als optiche aufheller, scintillatoren und laserfarbstoffe
JPS62267285A (ja) 1986-05-16 1987-11-19 Kyorin Pharmaceut Co Ltd 新規ピラゾロピリジン誘導体
DE59010069D1 (de) * 1989-11-21 1996-02-29 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
DE59005928D1 (de) 1989-11-21 1994-07-07 Bayer Ag Optischer Biosensor.
EP0448241A3 (en) 1990-02-28 1992-03-04 Konica Corporation Light-sensitive silver halide photographic material
CA2123740C (en) * 1993-05-19 2002-12-17 Hee-Gwon Chae Electric vacuum cleaner
JPH073179A (ja) * 1993-06-15 1995-01-06 Nippon Kayaku Co Ltd インクジェットプリント用インク組成物及びこれを用いる染色法
KR20040068240A (ko) 2001-12-14 2004-07-30 노보 노르디스크 에이/에스 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용
GB0205281D0 (en) * 2002-03-06 2002-04-17 Novartis Ag Organic compounds
CN1180016C (zh) 2002-04-04 2004-12-15 中国石化上海石油化工股份有限公司 用于制造增白聚丙烯纤维的增白聚丙烯母粒
KR100863667B1 (ko) * 2002-09-11 2008-10-15 가부시끼가이샤 구레하 아민 화합물 및 그 용도
US7399767B2 (en) * 2005-01-21 2008-07-15 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
AR059339A1 (es) * 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US8337941B2 (en) * 2006-07-27 2012-12-25 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
EP2121678B1 (en) * 2006-12-20 2010-11-03 NeuroSearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2009098209A1 (en) 2008-02-05 2009-08-13 Neurosearch A/S Novel 9-aza-bicyclo[3.3.1]non-3-yloxy chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
DE102008018132A1 (de) * 2008-04-09 2009-10-15 Henkel Ag & Co. Kgaa Kationische Direktzieher und Mittel zum Färben von keratinhaltigen Fasern
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2010019243A1 (en) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc. Methods for treating viral infections
KR101646804B1 (ko) 2008-10-29 2016-08-08 메르크 파텐트 게엠베하 액정 디스플레이
BR112014018027B1 (pt) 2012-01-26 2020-10-27 Ptc Therapeutics, Inc composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn
EP2812004B1 (en) 2012-02-10 2018-06-27 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
BR112014021531B1 (pt) 2012-03-01 2022-10-04 Ptc Therapeutics, Inc. Composto, composição farmacêutica e usos dos mesmos
CN104470909B (zh) 2012-03-23 2018-04-24 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物

Similar Documents

Publication Publication Date Title
JP2015504057A5 (enExample)
JP2020522570A5 (enExample)
JP2015508075A5 (enExample)
CN111182898B (zh) 用于治疗亨廷顿氏病的方法
JP7649257B2 (ja) ハンチントン病を処置するための化合物
AU2017204248B2 (en) Compounds for treating spinal muscular atrophy
EP3645121B1 (en) Methods for treating huntington's disease
JP2022153413A (ja) Rnaスプライシングを調節する方法
JP2011500774A5 (enExample)
JP2014506929A5 (enExample)
IL271046B2 (en) Compounds for the treatment of Huntington's disease
JPWO2019191229A5 (enExample)
RU2018112230A (ru) Бициклические соединения в качестве ингибиторов atx
HRP20120105T1 (hr) Aminoheterociklički spojevi
KR20140128310A (ko) 척수성 근위축증을 치료하기 위한 화합물
JP2016504363A5 (enExample)
RU2015131148A (ru) СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ
RU2014123316A (ru) Ингибиторы фосфодиэстеразы типа 10а
JPWO2020005877A5 (enExample)
JPWO2019191092A5 (enExample)
JP2020511412A5 (enExample)
JPWO2020065613A5 (enExample)
JPWO2022099144A5 (enExample)
NZ771342A (en) Heteroaryl compounds for treating huntington’s disease
NZ771342B2 (en) Heteroaryl compounds for treating huntington's disease